CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Background: Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple factors, including general efficacy, tolerability, potential for serious adverse events, comorbid conditions, and costs. Recently, a new class of migraine preventive drugs was introduced, i.e. monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor. Methods: The present article summarizes the evidence gathered with this new migraine preventive drug class from randomized placebo-controlled clinical trials. It further puts this into perspective next to the evidence gained by the most widely used agents for the prevention of episodic and chronic migraine with an emphasis on efficacy and the robustness with which this efficacy signal was obtained. Results: Although being a relatively new class of migraine preventive drugs, monoclonal antibodies blocking the CGRP pathway have an efficacy which is at least comparable if not higher than those of the currently used preventive drugs. Moreover, the robustness of this efficacy signal is substantiated by several randomized clinical trials each including large numbers of patients. In addition, because of their excellent tolerability and with long-term safety data emerging, they seem to have an unprecedented efficacy over adverse effect profile, clearly resulting in an added value for migraine prevention. Conclusions: Balancing the data presented in the current manuscript with additional data concerning long term safety on the one hand and cost issues on the other hand, can be of particular use to health policy makers to implement this new drug class in the prevention of migraine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although many well-evidenced medications exist, including newer targeted biologics, not all patients experience symptom relief, highlighting the need for additional treatment approaches.3”
From Acceptance-Commitment Therapy for Women with Episodic Migraine: A Pilot Randomized Trial (2024) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, D. D., Suzuki, K., Law, M., Trebicka, J., Neuhaus, J., Wentworth, D., Johnson, M., Vjecha, M. J., Kelleher, A. D., Emery, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139981 · Cited by 2,740
Aurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., Diener, H., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364676 · Cited by 1,047
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0003-1 · Cited by 999
Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H., & Brin, M. F. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01678.x · Cited by 994
Diener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., Silberstein, S., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364677 · Cited by 960
A Controlled Trial of Erenumab for Episodic Migraine
Goadsby, P. J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J. H., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1705848 · Cited by 928
Self-citationSilberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Fremanezumab for the Preventive Treatment of Chronic Migraine
Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709038 · Cited by 792
Tepper, S., Ashina, M., Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D., & Lenz, R. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30083-2 · Cited by 722
Self-citationTopiramate for Migraine Prevention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Brandes, J. L. (2004) · JAMA · doi:10.1001/jama.291.8.965 · Cited by 653
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
Dodick, D. W., Ashina, M., Brandes, J. L., Kudrow, D., Lanteri-Minet, M., Osipova, V., Palmer, K., Picard, H., Mikol, D. D., & Lenz, R. A. (2018) · Cephalalgia · doi:10.1177/0333102418759786 · Cited by 566
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Detke, H. C., Goadsby, P. J., Wang, S., Friedman, D. I., Selzler, K. J., & Aurora, S. K. (2018) · Neurology · doi:10.1212/wnl.0000000000006640 · Cited by 563
Dodick, D. W., Silberstein, S. D., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2018) · JAMA · doi:10.1001/jama.2018.4853 · Cited by 562
Diener, H.-C., Bussone, G., Oene, J. V., Lahaye, M., Schwalen, S., & Goadsby, P. (2007) · Cephalalgia · doi:10.1111/j.1468-2982.2007.01326.x · Cited by 561
Stauffer, V. L., Dodick, D. W., Zhang, Q., Carter, J. N., Ailani, J., & Conley, R. R. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1212 · Cited by 559
Skljarevski, V., Matharu, M., Millen, B. A., Ossipov, M. H., Kim, B.-K., & Yang, J. Y. (2018) · Cephalalgia · doi:10.1177/0333102418779543 · Cited by 531
Topiramate in Migraine Prevention: Results of a Large Controlled Trial
Silberstein, S. D. (2004) · Archives of Neurology · doi:10.1001/archneur.61.4.490 · Cited by 529
Silberstein, S. D., Lipton, R. B., Dodick, D. W., Freitag, F. G., Ramadan, N., Mathew, N., Brandes, J. L., Bigal, M., Saper, J., Ascher, S., et al. (2007) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00684.x · Cited by 497
Reuter, U., Goadsby, P. J., Lanteri-Minet, M., Wen, S., Hours-Zesiger, P., Ferrari, M. D., & Klatt, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32534-0 · Cited by 457
Self-citationAdherence to oral migraine-preventive medications among patients with chronic migraine
Hepp, Z., Dodick, D. W., Varon, S. F., Gillard, P., Hansen, R. N., & Devine, E. B. (2015) · Cephalalgia · doi:10.1177/0333102414547138 · Cited by 433
Ferrari, M. D., Diener, H. C., Ning, X., Galic, M., Cohen, J. M., Yang, R., Mueller, M., Ahn, A. H., Schwartz, Y. C., Grozinski-Wolff, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31946-4 · Cited by 417
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Lipton, R. B., Goadsby, P. J., Smith, J., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B., & Cady, R. (2020) · Neurology · doi:10.1212/wnl.0000000000009169 · Cited by 388
Blumenfeld, A. M., Bloudek, L. M., Becker, W. J., Buse, D. C., Varon, S. F., Maglinte, G. A., Wilcox, T. K., Kawata, A. K., & Lipton, R. B. (2013) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12055 · Cited by 380
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Ashina, M., Saper, J., Cady, R., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B., & Smith, J. (2020) · Cephalalgia · doi:10.1177/0333102420905132 · Cited by 380
Dodick, D. W., Goadsby, P. J., Silberstein, S. D., Lipton, R. B., Olesen, J., Ashina, M., Wilks, K., Kudrow, D., Kroll, R., Kohrman, B., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70209-1 · Cited by 372
Sacco, S., Bendtsen, L., Ashina, M., Reuter, U., Terwindt, G., Mitsikostas, D.-D., & Martelletti, P. (2019) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0955-y · Cited by 370
Self-citationDodick, D. W., Goadsby, P. J., Spierings, E. L. H., Scherer, J. C., Sweeney, S. P., & Grayzel, D. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70128-0 · Cited by 368 · cited 1×
“The first phase 2 trials with CGRP mAb were published in 2014 (eptinezumab and galcanezumab) [8, 16].”
BackgroundGuidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators
International Headache Society Clinical Trials Subcommittee members:, Tfelt-Hansen, P., Pascual, J., Ramadan, N., Dahlöf, C., D'Amico, D., Diener, H.-C., Hansen, J. M., Lanteri-Minet, M., Loder, E., et al. (2012) · Cephalalgia · doi:10.1177/0333102411417901 · Cited by 365
Hepp, Z., Dodick, D. W., Varon, S. F., Chia, J., Matthew, N., Gillard, P., Hansen, R. N., & Devine, E. B. (2017) · Cephalalgia · doi:10.1177/0333102416678382 · Cited by 359
Sun, H., Dodick, D. W., Silberstein, S., Goadsby, P. J., Reuter, U., Ashina, M., Saper, J., Cady, R., Chon, Y., Dietrich, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00019-3 · Cited by 358
Self-citationTronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2003) · JAMA · doi:10.1001/jama.289.1.65 · Cited by 355
Diener, H.-C., Tfelt-Hansen, P., Dahl�f, C., L�inez, M. J. A., Sandrini, G., Wang, S.-J., Neto, W., Vijapurkar, U., Doyle, A., Jacobs, D., et al. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0464-6 · Cited by 343
Amitriptyline in Migraine Prophylaxis
Couch, J. R., & Hassanein, R. S. (1979) · Archives of Neurology · doi:10.1001/archneur.1979.00500470065013 · Cited by 334
Systematic Review of Migraine Prophylaxis Adherence and Persistence
Hepp, Z., Bloudek, L. M., & Varon, S. F. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.1.22 · Cited by 333
Migraine Prophylaxis With Divalproex
Mathew, N. T., Saper, J. R., Silberstein, S. D., Rankin, L., Markley, H. G., Solomon, S., Rapoport, A. M., Silber, C. J., & Deaton, R. L. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540270077022 · Cited by 329
A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
Jackson, J. L., Cogbill, E., Santana-Davila, R., Eldredge, C., Collier, W., Gradall, A., Sehgal, N., & Kuester, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130733 · Cited by 291
Sodium Valproate in The Prophylactic Treatment of Migraine: A Double-Blind Study Versus Placebo
Hering, R., & Kuritzky, A. (1992) · Cephalalgia · doi:10.1046/j.1468-2982.1992.1202081.x · Cited by 282
Divalproex Sodium in Migraine Prophylaxis: A Dose-Controlled Study
Klapper, J., & on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group (1997) · Cephalalgia · doi:10.1046/j.1468-2982.1997.1702103.x · Cited by 280
A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis
Freitag, F. G., Collins, S. D., Carlson, H. A., Goldstein, J., Saper, J., Silberstein, S., Mathew, N., Winner, P. K., Deaton, R., & Sommerville, K. (2002) · Neurology · doi:10.1212/wnl.58.11.1652 · Cited by 274
Mulleners, W. M., Kim, B.-K., Láinez, M. J. A., Lanteri-Minet, M., Pozo-Rosich, P., Wang, S., Tockhorn-Heidenreich, A., Aurora, S. K., Nichols, R. M., Yunes-Medina, L., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30279-9 · Cited by 270
Bigal, M. E., Edvinsson, L., Rapoport, A. M., Lipton, R. B., Spierings, E. L. H., Diener, H.-C., Burstein, R., Loupe, P. S., Ma, Y., Yang, R., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00245-8 · Cited by 261
Jensen, R., Brinck, T., & Olesen, J. (1994) · Neurology · doi:10.1212/wnl.44.4.647 · Cited by 238
Topiramate in Migraine Prevention: A Double‐Blind, Placebo‐Controlled Study
Storey, J. R., Calder, C. S., Hart, D. E., & Potter, D. L. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.01190.x · Cited by 196
The treatment of migraine with propranolol
Weber, R. B., & Reinmuth, O. M. (1972) · Neurology · doi:10.1212/wnl.22.4.366 · Cited by 182
Stovner, L. J., Linde, M., Gravdahl, G. B., Tronvik, E., Aamodt, A. H., Sand, T., & Hagen, K. (2014) · Cephalalgia · doi:10.1177/0333102413515348 · Cited by 174
Skljarevski, V., Oakes, T. M., Zhang, Q., Ferguson, M. B., Martinez, J., Camporeale, A., Johnson, K. W., Shan, Q., Carter, J., Schacht, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3859 · Cited by 172
Gonçalves, A. L., Martini Ferreira, A., Ribeiro, R. T., Zukerman, E., Cipolla-Neto, J., & Peres, M. F. P. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313458 · Cited by 169
Topiramate for the prophylaxis of episodic migraine in adults
Linde, M., Mulleners, W. M., Chronicle, E. P., & McCrory, D. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010610 · Cited by 164
Topiramate in the Treatment of Chronic Migraine
Silvestrini, M., Bartolini, M., Coccia, M., Baruffaldi, R., Taffi, R., & Provinciali, L. (2003) · Cephalalgia · doi:10.1046/j.1468-2982.2003.00592.x · Cited by 162
Amitriptyline in the Prophylactic Treatment of Migraine and Chronic Daily Headache
Couch, J. R., & for the Amitriptyline Versus Placebo Study Group (2010) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01800.x · Cited by 158
Linde, M., Mulleners, W. M., Chronicle, E. P., & McCrory, D. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010611 · Cited by 157
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
Dodick, D. W., Lipton, R. B., Silberstein, S. D., Goadsby, P. J., Biondi, D. M., Hirman, J., Cady, R. K., & Smith, J. (2019) · Cephalalgia · doi:10.1177/0333102419858355 · Cited by 155
Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis
Peters, R., Yasar, S., Anderson, C. S., Andrews, S., Antikainen, R., Arima, H., Beckett, N., Beer, J. C., Bertens, A. S., Booth, A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000008732 · Cited by 153
Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial
Tfelt-Hansen, P., Standnes, B., Kangasneimi, P., Hakkarainen, H., & Olesen, J. (1984) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1984.tb07772.x · Cited by 146
A Comparison of Divalproex With Propranolol and Placebo for the Prophylaxis of Migraine Without Aura
Kaniecki, R. G. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550210071015 · Cited by 127
DOUBLE BLIND STUDY OF PROPRANOLOL FOR MIGRAINE PROPHYLAXIS
Diamond, S., & Medina, J. L. (1976) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.1976.hed1601024.x · Cited by 106
Antiepileptics in migraine prophylaxis: An updated Cochrane review
Mulleners, W. M., McCrory, D. C., & Linde, M. (2014) · Cephalalgia · doi:10.1177/0333102414534325 · Cited by 103
Sakai, F., Suzuki, N., Kim, B., Tatsuoka, Y., Imai, N., Ning, X., Ishida, M., Nagano, K., Iba, K., Kondo, H., et al. (2021) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14178 · Cited by 101
Sakai, F., Suzuki, N., Kim, B., Igarashi, H., Hirata, K., Takeshima, T., Ning, X., Shima, T., Ishida, M., Iba, K., et al. (2021) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14169 · Cited by 97
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
Sakai, F., Takeshima, T., Tatsuoka, Y., Hirata, K., Lenz, R. A., Wang, Y., Cheng, S., Hirama, T., & Mikol, D. D. (2019) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13652 · Cited by 93
Propranolol in the Treatment of Migraine
Widerøe, T., & Vigander, T. (1974) · BMJ · doi:10.1136/bmj.2.5921.699 · Cited by 83
Silberstein, S. D., Hulihan, J. F., REZAULKARIM, M., WU, S., JORDAN, D., Karvois, D. L., & Kamin, M. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.003 · Cited by 77
Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study
Mei, D., Capuano, A., Vollono, C., Evangelista, M., Ferraro, D., Tonali, P., & Di Trapani, G. (2004) · Neurological Sciences · doi:10.1007/s10072-004-0350-0 · Cited by 72
Lipton, R. B., Silberstein, S. D., Dodick, D. W., Cady, R. K., Freitag, F. G., Mathew, N. T., Biondi, D. M., Ascher, S., Olson, W. H., & Hulihan, J. F. (2010) · Cephalalgia · doi:10.1177/0333102410372427 · Cited by 70
PROPRANOLOL FOR MIGRAINE PROPHYLAXIS
Forssman, B., Henriksson, K., Johannsson, V., Lindvall, L., & Lundin, H. (1976) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.1976.hed1605238.x · Cited by 69
Drug safety and tolerability in prophylactic migraine treatment
Vécsei, L., Majláth, Z., Szok, D., Csáti, A., & Tajti, J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1014797 · Cited by 66
Long-Acting Propranolol in Migraine Prophylaxis: Results of a Double-Blind, Placebo-Controlled Study
Pradalier, A., Serratrice, G., Collard, M., Hirsch, É., Fève, J. R., Masson, M., Masson, C., Dry, J., Koulikovsky, G., Nguyen, G.-T., et al. (1989) · Cephalalgia · doi:10.1046/j.1468-2982.1989.0904247.x · Cited by 65
Stensrud, P. A., & Sjaastad, O. (1976) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1976.tb04342.x · Cited by 65
Andersson, P. G., Dahl, S., Hansen, J. H., Hansen, P. E., Hedman, C., Kristensen, T. N., & Olivarius, B. D. F. (1983) · Cephalalgia · doi:10.1046/j.1468-2982.1983.0304207.x · Cited by 65
Wang, S., Roxas, A., Saravia, B., Kim, B., Chowdhury, D., Riachi, N. J., Tai, M. S., Tanprawate, S., Ngoc, T. T., Zhao, Y. J., et al. (2021) · Cephalalgia · doi:10.1177/03331024211024160 · Cited by 65
Steiner, T. J., Joseph, R., Hedman, C., & Rose, F. C. (1988) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1365-2524.1988.hed2801015.x · Cited by 63
Classic Migraine: Effective Prophylaxis with Metoprolol
Kangasniemi, P., Ar, A., Andersson, P. G., Ne, G., Hedman, C., Hultgren, M., Vilming, S. T., & Olesen, J. (1987) · Cephalalgia · doi:10.1046/j.1468-2982.1987.0704231.x · Cited by 61
Schoenen, J. E., Manise, M., Nonis, R., Gérard, P., & Timmermans, G. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.04.027 · Cited by 59
Self-citationA Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine
Reuter, U. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13302 · Cited by 57
Self-citationCyclandelate in the Prophylaxis of Migraine
Diener, H., F”h, M., Laccarino, C., Wessely, P., Isler, H., Stienge, H., Fischer, M., Wedekind, W., & Taneri, Z. (1996) · Cephalalgia · doi:10.1046/j.1468-2982.1996.1606441.x · Cited by 53
Zhu, Y., Liu, Y., Zhao, J., Han, Q., Liu, L., & Shen, X. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3547-3 · Cited by 52
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
Han, L., Liu, Y., Xiong, H., & Hong, P. (2019) · Brain and Behavior · doi:10.1002/brb3.1215 · Cited by 52
Forbes, R. B., McCarron, M. O., & Cardwell, C. R. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13907 · Cited by 48
Siniatchkin, M., Andrasik, F., Kropp, P., Niederberger, U., Strenge, H., Averkina, N., Lindner, V, Stephani, U., & Gerber, W.-D. (2007) · Cephalalgia · doi:10.1111/j.1468-2982.2007.01377.x · Cited by 42
Methodological Aspects of Drug Trials in Migraine. pp 204–215
Tfelt-Hansen, P., & Olesen, J. (1985) · Neuroepidemiology · doi:10.1159/000110232 · Cited by 41
Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis
Al-Asa'd, Y., & Asha, M. Z. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.105900 · Cited by 41
Propranolol in the Prophylaxis of Migraine
Nadelmann, J., Phil, M., Stevens, J., & Saper, J. R. (1986) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.1986.hed2604175.x · Cited by 40
Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo
Mikkelsen, B. O., Pedersen, K. K., & Christiansen, L. V. (1986) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1986.tb03299.x · Cited by 40
de Tommaso, M., Guido, M., Sardaro, M., Serpino, C., Vecchio, E., Stefano, G. D., Claudio, T. D., Specchio, L. M., & Livrea, P. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.076 · Cited by 38
Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis
Johnson, R. H., Hornabrook, R. W., & Lambie, D. G. (1986) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1986.tb04591.x · Cited by 36
Long-Acting Propranolol in Migraine Prophylaxis: Results of a Double-Blind, Placebo-Controlled Study
Pradalier, A., Serratrice, G., Collard, M., et al. (1989) · Cephalalgia · doi:10.1046/j.1468-2982.1989.904247.x · Cited by 35
Prophylactic Treatment Of Migraine With Long Acting Propranolol - A Comparison With Placebo
Kuritzky, A., & Hering, R. (1987) · Cephalalgia · doi:10.1177/03331024870070s6203 · Cited by 22
Positive affective priming decreases the middle late positive potential response to negative images
Hill-Bowen, L. D., Starratt, V. G., Fernandez, M., & Tartar, J. L. (2018) · Brain and Behavior · doi:10.1002/brb3.1198 · Cited by 21
Evans, K., Romero, H., Spierings, E. L. H., & Katz, N. P. (2020) · Cephalalgia · doi:10.1177/0333102420960020 · Cited by 16
Propranolol in prophylaxis of migraine.
Gk, A., & Verma, A. K. (1985) · PubMed · Cited by 11
Treatment of migraine with propranolol.
Borgesen, S. E. (1976) · PubMed · Cited by 9
[Preventive treatment for migraine].
Mulleners, W. M., Haan, J., Dekker, F., & Ferrari, M. D. (2010) · PubMed · Cited by 4
Preventie van NSAID-gastropathie: verschil tussen een coxib en toevoeging van een PPI
Lems, W. F., & Kuipers, E. J. (2010) · Pure Amsterdam UMC · Cited by 4
Research works printed but not linked: 2
- Mulleners WM Haan J Dekker F Jko T Wbo H Tqfdjgjfl B Preventieve behandeling van migraine Ned Tijdschr Geneeskd 2010 154 1 9 20699036
- Solomon GDSA Verapamil and propranolol in migraine prophylaxis: a double-blind, cross over study Headache. 1986 26 325
Cited by
Sacco, S., Amin, F. M., Ashina, M., Bendtsen, L., Deligianni, C. I., Gil-Gouveia, R., Katsarava, Z., MaassenVanDenBrink, A., Martelletti, P., Mitsikostas, D.-D., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01431-x · Cited by 410
“Among the oral prophylactics, high dropout rates were reported especially for amitriptyline, valproate or topiramate [37].”
BackgroundSelf-citationYang, D., Jacobson, A., Meerschaert, K. A., Sifakis, J. J., Wu, M., Chen, X., Yang, T., Zhou, Y., Anekal, P. V., Rucker, R. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.024 · Cited by 224
Lampl, C., MaassenVanDenBrink, A., Amin, F. M., Deligianni, C. I., Gil-Gouveia, R., Jassal, T., Sanchez-Del-Rio, M., Reuter, U., Uluduz, D., Versijpt, J., et al. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01594-1 · Cited by 183
Self-citationBarbanti, P., Egeo, G., Aurilia, C., Altamura, C., d’Onofrio, F., Finocchi, C., Albanese, M., Aguggia, M., Rao, R., Zucco, M., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01498-6 · Cited by 111
“Their distinguishing feature is the considerable proportions of responders (≥ 50% reduction in monthly migraine days) and super-responders (≥ 75% reduction in monthly migraine days), and the excellent efficacy and tolerability ratio which represents a substantial step forward compared to the usual standard of care [3,…”
BackgroundCalcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
Versijpt, J. J., Paemeleire, K., Reuter, U., & MaassenVanDenBrink, A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00109-6 · Cited by 94
Self-citation
Metadata
- Authors
- Vandervorst, F., Van Deun, L., Van Dycke, A., Paemeleire, K., Reuter, U., Schoenen, J., & Versijpt, J.
- Affiliations
- Vrije Universiteit Brussel (BE)
- Ghent University Hospital (BE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- University of Liège (BE)
- Corresponding author
- Versijpt, Jan
- Venue
- The Journal of Headache and Pain
- Published
- 2021-10-25
- Volume
- 22
- Issue
- 1
- Pages
- 128-128
- ISSN
- 1129-2369 (ISSN-L)
- 1129-2377
- PMC
- PMC8547103
- OpenAlex
- W3208701883
- Cited by
- 121
- References
- 94
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 19 · 2023: 36 · 2022: 34 · 2021: 1
- FWCI
- 16.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- The Journal of Headache and Pain (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Dentistry › Oral Surgery › Temporomandibular Joint Disorders
- Keywords
- migraine prophylaxis, CGRP monoclonal antibodies, calcitonin gene-related peptide, CGRP receptor antagonists, episodic migraine, chronic migraine, drug efficacy, tolerability, adverse events, long-term safety, cost-effectiveness, health policy
- MeSH terms
- Antibodies, Monoclonal, Calcitonin, Pharmaceutical Preparations, Humans, Migraine Disorders, Calcitonin Gene-Related Peptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.